http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#Head http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#provenance http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#pubinfo http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion http://purl.obolibrary.org/obo/DOID_8536 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8536 http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00299 http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association http://www.w3.org/2000/01/rdf-schema#label famciclovir a prodrug of penciclovir is a nucleoside analog dna polymerase inhibitor indicated for immunocompetent adult patients 1 1 herpes labialis cold sores treatment of recurrent episodes genital herpes treatment of recurrent episodes suppressive therapy of recurrent episodes herpes zoster shingles hiv infected adult patients 1 2 treatment of recurrent episodes of orolabial or genital herpes limitation of use 1 3 the efficacy and safety of famciclovir have not been established for patients 18 years of age immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes herpes labialis cold sores genital herpes recurrent episodes suppressive therapy herpes zoster shingles recurrent orolabial or genital herpes famciclovir tablets are indicated for the treatment of recurrent episodes of orolabial or genital herpes in hiv infected adults the efficacy of famciclovir tablets when initiated more than 48 hours after onset of symptoms or lesions has not been established the efficacy and safety of famciclovir tablets have not been established for patients 18 years of age patients with first episode of genital herpes patients with ophthalmic zoster immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in hiv infected patients black and african american patients with recurrent genital herpes http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00299 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#provenance http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#pubinfo http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig http://purl.org/nanopub/x/hasSignature HVdu8i+illjVM1vNKw9G1EyBQ/mpjnAxmkl5VCd0v/6/1rEghDeX0iZvLdwiAgdV+ao7LNkcW/iwS4h/R+LPsGE54Ldia0wk9IBX5YmS0lXiJgeRa+MIMlrDbRoyKRRxxWQ1zDOWIrSqsRwdICDqTkgqXlwRrnclmydRRG6IlEk= http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://purl.org/dc/terms/created 2021-06-15T18:34:09.095+02:00 http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAn_YBe__x2syrmZQrYl_g5aPDqQjqqdx1lQMHsJrKGVA https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs